Identification of antigenic variants of the PorA protein of Neisseria meningitidis with specific mAbs (serosubtyping) is used in meningococcal strain characterization and the resultant data has been exploited in the design of novel multivalent vaccines against this important pathogen. The reactivity of the P1.10 serosubtyping mAb MNZOF4.17 with eight members of the meningococcal P I .10 variable region (VR) family (prototype P1.10 and variants P1 .lOa-Pl.lOg), identified by nucleotide sequence analysis of porA genes, was investigated. Analysis of overlapping synthetic octapeptides by ELISA demonstrated that the peptide sequence, QNQRPTL, present only in the prototype P1.10, was sufficient for binding of the mAb. A linear peptide of 14 amino acids, containing the minimum epitope, inhibited binding of mAb MNZOF4.17 to whole cells in a competitive ELISA. This binding was weak compared with a tethered peptide or the native protein. In whole-cell ELISA or dot-blot assays using low concentrations of mAb MNZOF4.17 only the prototype P1.10 was detected. However, when higher concentrations of antibody were used the prototype P1.10 was detected, together with variants Pl.lOa, P l . 1 0~ and Pl.lOe by whole-cell ELISA and Pl.lOa and P l . 1 0~ by the immunoblot technique. The variants Pl.lOb, Pl.lOd, Pl.lOf and Pl.lOg showed no reactivity with mAb under any of the conditions tested. A survey of the porA genes in serogroup B and C strains revealed that the Pl.lOa variant, rather than the prototype P1.10, was the most common member of the P1.10 VR family in England and Wales. These data illustrate: (i) the problems associated with epidemiological analyses that rely solely on monoclonal antibodies; (ii) the importance of using defined assay conditions for serosubtyping ; and (iii) that genetical analyses provide more reliable information than serological data based on murine reagents for the design of candidate vaccines that include PorA.
INTRODUCTION
diseases, which affect only a small proportion of meningococcal carriers, requires swift diagnosis and compreBacterial meningitis and septicaemia, caused by the human pathogen Neisseria meningitidis, are characterized by rapid onset and a high mortality rate (Peltola, 1983 ; Bannister, 1988; Hart & Rogers, 1993) . The management of these hensive surveillance (Broome, 1986 ; Schwartz e t al., 1989 ; Caugant et al., 1994) . Murine mAbs are employed for the routine epidemiological characterization of meningococci by the identification of antigenic variants of the PorA protein, a porin (Abdillahi & Poolman, 1987 ,1988a . This protein is also a major component of several antimeningococcal vaccines included in clinical trials (Fine, 0002-0222 0 1996 SGM 1991; Sierra e t al., 1991; van der Ley et al., 1995) . However, many isolates fail to react with the current set of mAbs and new approaches are required to identify these strains for epidemiological analysis and to provide data for vaccine design and assessment.
The application of molecular techniques, such as direct nucleotide sequence determination, permits the characterization of meningococcal PorA variants by deduced amino acid sequence rather than by antibody reactivity (Suker et al., 1994) . The term 'subtype' is best used to refer to PorA proteins characterized by the deduction of their amino acid sequences from nucleotide sequence data and ' serosubtype ' to indicate characterization solely by mAbs. Comparative and immunological studies have shown that subtypes reside in two variable regions (VRs), designated VR1 and VR2, of PorA which correspond to surface loops I and IV of the proposed porin structure (Barlow e t al., 1989; McGuinness et al., 1990 McGuinness et al., , 1993 Butcher e t al., 1991 ; van der Ley & Poolman, 1991 ; van der Ley etal., 1991 ; Maiden etal., 1991 ; Suker etal., 1994) . Distinct VR1 and VR2 peptide sequences are assigned arbitrary numbers and confer a dual subtype designation given after the prefix 'Pl. ', e.g. P1.5,10, where 5 is located in VR1 and 10 in VR2.
The accumulation of mutations in the subtype-encoding regions of the porA gene results in VR 'families' that comprise related peptide sequences (Suker e t al., 1994) . The minor variants are distinguished by the addition of a lower case letter after the subtype designation; e.g., P1.10a. Continuous peptide epitopes within the subtype sequences that are recognized by the serosubtyping mAbs have been defined for a number of the VR families (McGuinness e t al., 1990 (McGuinness e t al., , 1993 . However, small amino acid changes in the VR families may result in the loss or sequestration of these epitopes in some variants (McGuinness et al., 1991 (McGuinness et al., , 1993 Wedege e t al., 1993) .
The present work was undertaken to define the reactivity of members of the P1.10 VR family with serosubtyping mAb MN20F4.17. The P1.10 family was chosen as it is widely distributed in meningococci and the prototype P1.10 sequence is included in a multivalent PorA vaccine (van der Ley et al., 1995) . The minimum amino acid sequence recognized by the P1.10 serosubtyping mAb MN20F4.17 was defined and the immunological reactivities of this antibody with eight members of the P1.10 VR family were compared by ELISA and immunoblotting. The relative contributions of amino acid sequence and epitope conformation in serosubtype recognition were investigated by immunoassay of membrane preparations subjected to boiling in SDS and by a competitive ELISA of a linear peptide with protein in its native conformation. Finally, the distribution of members of the P1.10 VR family among serotyped P1.10 and nonserotypeable serogroup B and C strains was determined by comparative analyses ofporA genes. These data show that for the P1.10 VR family serosubtyping with mAb underestimates the antigenic diversity of PorA. We conclude that multivalent PorA vaccines designed on the basis of serosubtype data alone may not necessarily contain the most appropriate variant of a given VR family.
METHODS
Bacterial strains. Meningococcal strains used in this study were provided by the Public Health Laboratory, Withington Hospital, Manchester and by the Max-Planck Institut fur molekulare Genetik, Berlin. The nine strains in Table 1 Maiden, unpublished results) . The strains from these surveys were also used for the assessment of porA diversity. Strain 21388 was chosen as a negative control strain as itsporA gene is identical to that encoding the prototype P1.10 (21040) except for an 87 bp deletion which removes VR2 (Suker e t af., 1994). The VR2 sequences of the eight P1.10 variant strains were confirmed by direct nucleotide sequence analysis prior to this study using the method of Suker et af. (1994) (v/v) glycerol; 3 mM sodium citrate; 1 mM ammonium sulphate; 1 mM magnesium sulphate; 100 mM potassium phosphate, pH 6-61. The bacteria were propagated on heated blood (chocolate) agar at 37 "C in a 5 YO (v/v) CO, atmosphere for 8-16 h. Preparation of DNA from meningococcal strains was performed using an Isoquick Kit (Microprobe) by the rapid DNA extraction protocol provided by the manufacturer. Cells were suspended in 500 pl sample buffer (Microprobe) to approximately lo8 cells ml-'. Larger scale preparation of DNA was done by scraping the growth from five chocolate agar plates and resuspending the bacteria in 5 ml TE buffer (10 mM Tris/HCl containing 1 mM EDTA, pH 8.0) to which 5 ml 100 mM Tris/HCl, pH 7.5, containing 100 mM NaC1, 10 mM EDTA and 1 % (v/v) Sarkosyl was added. Proteinase I< was added to a final concentration of 100 pg ml-' and the samples were incubated at 55 "C for 2 h. The mixture was then extracted once with phenol, once with phenol/chloroform and once with chloroform. Boiled RNase A (final concentration 100 pg ml-') was added to the extract which was incubated at room temperature for 2 h. The samples were again extracted with phenol, phenol/chloroform and chloroform and dialysed overnight against two changes of 0.1 x TE buffer. The DNA concentration and purity were estimated spectrophotometrically before use. PCR. Reaction components were as follows : 50 ng template DNA pl-'; 10 mM Tris/HCl, pH 8.0; 50 mM KC1; 1.5 mM MgC1, ; 0.001 % gelatin ; 200 pM of each of dATP, dCTP, dGTP and dTTP; 2 pM of each of the required primers and 0.5 U Taq polymerase (Amplitaq, Cetus). The components were incubated for 30 cycles in a programmable heat block (PHC-2, Techne Instruments) for 2 min at 94 "C, 2 min at 68 "C or 70 "C and 3 min at 72 "C. At the end of 30 cycles, the reaction mixtures were incubated for 3 min at 72 "C. Gene fingerprinting by chain termination. Fingerprints from PCR products were produced by the method of Suker e t af. (1994) . Dideoxy termination reactions were run on adjacent tracks of polyacrylamide gels and compared. For example, 'T- track ' fingerprints were produced by running dideoxythymidine reactions in adjacent lanes. Separate fingerprints were determined for extension reactions terminated with dideoxythymidine, dideoxyguanine and dideoxycytosine.
Membrane preparation and protein analysis. Membranes of N. meningitidis were prepared by a modification of the sphaeroplast lysis method (Witholt et al., 1976) . A single colony from a chocolate agar plate was inoculated into 5 ml Muller-Hinton broth and grown for 6 h at 37 O C until an OD,,, of 0.6 (approx. 5 x 10' cells ml-l) was obtained. Cells from 4 ml culture were harvested and resuspended in 200 p1 200 mM Tris/HCl containing 1 mM EDTA, pH 8.0. To this suspension was added 200 pl 200 mM Tris/HCl containing 1 M sucrose and 1 mM EDTA. After mixing for 90 s, 24 pg egg white lysozyme was added followed by 400 pl deionized water after a further 45 s. The suspension was incubated at room temperature with gentle mixing for 30 min. The sphaeroplasts formed were collected by centrifugation at 40000g for 20 min at 20 O C , and lysed by the addition of 800 pl ice-cold deionized water. The membranes were collected by centrifugation as above and resuspended in 400 pl deionized water. Protein concentrations were estimated by the bicinchoninic acid method using reagents from a BCA kit (Pierce) with BSA as a standard. Membrane proteins were separated on a 12.5% (w/v) acrylamide gel and visualized by staining with Coomassie Brilliant Blue.
Source of mAb MNZOF4.17. The mAb was used in the form of ascitic fluid, collected from pristane-treated mice after intraperitoneal injection with cells of the hybridoma cell line MN20F4.17, provided by Dr J. T. Poolman of the National Institute for Public Health and Environmental Protection, Bilthoven, The Netherlands (Poolman et al., 1995) . Ascitic fluid was stored at -20 "C. Purified antibody was obtained from the ascitic fluid by precipitation with 45% (w/v) ammonium sulphate solution followed by separation on a protein G column.
ELISA. ELISAs were carried out by a modified version of the method of Abdillahi & Poolman (1987) . Chocolate agar plates were spread with 100 p1 cells from frozen stocks and incubated at 37 O C in 5 % CO, atmosphere overnight. For each strain, 5 ml Muller-Hinton broth was inoculated and incubated at 37 O C in a shaking incubator for 8 h or until an OD,,, of 0.6 was obtained. Cells were harvested from 3 ml broth culture by centrifugation for 10 min in a microfuge and resuspended in 1 ml PBS containing 0.05% Tween 20. The cell suspensions were heated at 55 "C for 30 min to kill the cells and then diluted 1 :10 in PBS (1.6 x lo8 cells ml-'). Diluted cell suspensions were stored at 4 "C for up to 7 d. For ELISA, Nunc 96-well flatbottomed microtitre plates were freshly coated for each test with 100 p1 per well of the cell suspension and allowed to dry at 37 O C overnight. The plates were washed three times with 0.025% Tween 20. Decimal dilutions of mAb MN20F4.17 (100 pl per well) were added to the plate which was incubated at 37 OC for 1 h. The plate was again washed three times with 0.025% Tween 20. Secondary conjugate (Protein A-peroxidase, 100 pl per well) diluted 1:2500 in PBS containing 0.5% BSA and 0.01 % Tween 20, was added and the plate incubated at 37 OC for 1 h. The plate was finally washed with 0-025 % Tween 20. ABTS [2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) diammonium salt, 0.5 mg ml-'] was made up in 0.05 M citric acid, pH 4-0, containing 0.006% hydrogen peroxide and added to the plate (150 pl per well). The colour was allowed to develop for 10 min and the A,,, was measured. For the inhibition ELISA, 100 p1 aliquots of purified mAb MN20F4.17 (either 55 or 550 ng ml-l) were mixed with 100 p1 aliquots 0-10 mg peptide ml-' before addition to the whole-cell-coated plate. Dot-immunoblotting. Membrane samples were prepared as above and various dilutions made. For non-denatured samples, dilutions were made in PBS; for denatured samples, dilutions were made in transfer buffer minus methanol [25 mM Tris/HCl containing 0.19 M glycine and 0.1 % SDS] and boiled for 5 min.
A nitrocellulose membrane, presoaked in PBS, was placed in a dot-blot manifold (Bio-Rad), 100 pl samples were applied to the wells and drawn on to the membrane under vacuum. The membrane was cut in half; the portion with non-denatured samples was rinsed in PBS, the portion with denatured samples was rinsed in transfer buffer containing 20 YO (v/v) methanol to remove traces of SDS. Both filters were blocked in PBS containing 5 % (w/v) powdered milk for 1 h at 25 "C and incubated for 16 h with dilutions of mAb MN20F4.17 in PBS/milk (usually 1 : 100). After rinsing in several changes of PBS, the filters were incubated for 1 h with Protein h-peroxidase conjugate, diluted 1 : 1000 in PBS/milk. Following further washes in PBS, dots were visualized by immersing the filters in 0.35 mM 4-chloronaphthol in 1 6 % methanol and 20 mM Tris/HCl, pH 7.4.
Epitope scanning. A set of synthetic peptides was synthesized on the tips of derivatized polyethylene pins in the configuration of a 96-well microtitre plate using the Pin Technology method [Cambridge Research Biochemicals ; Geysen et al.
( 1 987)]. Each peptide was eight amino acids long and overlapped with the next consecutive peptide by seven amino acids. The synthesis schedule (General Net strategy) was designed so that all known variants of the P1.10 epitope were covered with an overlap of one amino acid. The peptide-bearing pins were blocked for 16 h in 2 YO (w/v) BSA at 4 "C and then reacted in an ELISA with purified P1.10 antibody using 440 ng IgG per peptide. Antimouse IgG-peroxidase conjugate was used as a secondary antibody and binding was detected with ABTS as a substrate. A405 was measured and plotted against peptide sequence.
RESULTS P I . I 0 variants show different reactivities with mAb MN20F4.17
The reactivities of nine meningococcal strains (Table 1) with mAb MN20F4.17 were assessed by ELISA and immunoblotting. When high concentrations of mAb MN20F4.17 were used (1 : 10 dilution of ascitic fluid containing mAb or 20 pg purified IgG per well), strains expressing four of the variant PorA proteins examined, prototype P1.10, Pl.lOa, Pl.lOc and Pl.lOe, bound antibody at levels detectable in whole-cell ELISA. At lower antibody concentrations only strain 2 1 040, expressing the prototype P1.10, bound antibody at levels detectable by this assay (Fig. 1). 3.5 I 4 \ \ 0*5 10-1 * 10-2 10-3 10-4 10-5 10-6 10-7 Dilution of mAb MNZOF4.17 Fig. 2 lmmunoblot of members of the P1.10 variable region family with the P1.10 specific mAb, MNZOF4.17. Filters were prepared in a dot-blot manifold using doubling dilutions of membrane samples (6-50 pg total protein per dot) from strains expressing PorA proteins with the prototype P1.10 and variants Pl.lOa-P1 .log. (a) Non-denaturing conditions, PBS was used for dilution of samples and to wash the filter following transfer; (b) denaturing conditions, SDS-containing buffer was used for dilution and boiling of samples and t o wash the filter following transfer. Each filter was probed with ascitic fluid containing mAb MNZOF4.17 a t a dilution of 1 : 100.
Immunoblotting experiments showed that mAb MN20F4.17 bound to native membrane samples of strains expressing the prototype P1.10, Pl.lOa and Pl.lOc, although the signals obtained with the variant strains were weaker than that obtained with the prototype strain (Fig. 2a) . When membrane samples boiled in SDScontaining buffer were used, only membranes from the strain expressing the prototype P1.10 sequence reacted with the antibody at detectable levels (Fig. 2b) .
In whole-cell ELISA, the prototype P1.10 was detected by up to 1 : 10000 dilution of ascitic fluid (Fig. 1) or 2 ng purified IgG per well (data not shown). The P1.10 variants which differed from the prototype P1.10 by only one amino acid (Pl.lOa, P 1 . 1 0~ and Pl.lOe) were only reliably detected at 1 : l O dilution of mAb MN20F4.17. Four variants were never detected by the mAb; these differed from the prototype sequence by either two (variant Pl.lOg), four (variants Pl.lOb and Pl.lOd) or seven (variant Pl.lOf) amino acids (Table 1) . (0) and each of the variants Pl.lOa (e), Pl.10~ ( 0 ) and Pl.lOe (m) . The background reading from mAb-binding to whole cells of the P1 .lo-deleted negative control strain (Z1388) has been subtracted, hence variants Pl.lOb, Pl.lOd, Pl.lOf and Pl.lOg do not appear on the graph as binding to these strains was not above background levels under these conditions. Amino acid sequence QNQRPTL identified as the minimum P1.10 epitope reactive with mAb MN20F4.17
The minimum amino acid sequence responsible for the P1.10 epitope was defined by means of a set of overlapping peptides synthesized on the tips of polyethylene pins. Based on the amino acid sequences of the eight variants of 
Amino acid sequences of peptides Fig. 3 . Localization of the minimum epitope required for P1.10 subtype specificity of mAb MN2OF4.17. A set of tethered overlapping synthetic peptides of eight amino acids in length, differing by one amino acid and based on the sequences of the eight P1.10 variants, were reacted in ELISA with purified P1.10 antibody using 440 ng IgG per peptide. The amino acid sequences of the peptides (printed vertically) which showed greatest reactivity are plotted against A405. The putative minimum epitope sequence is shown in bold and underlined. the P1.10 VR family, 91 peptides of eight amino acids in length, overlapping by seven amino acids, were synthesized. The last two amino acids (VP) of the P1.10 VR were omitted from the synthesis schedule as these occur in all variants and it was assumed that they did not contribute to the minimum epitope. The peptide-bearing pins were reacted in ELISA with mAb MN20F4.17 (Fig. 3) . The ELISA profile showed that most reactivity with the anti-P1.10 antibody occurred with the peptide of sequence KQNQRPTL and comparison with the other peptides showed that the sequence QNQRPTL was sufficient for binding of mAb MN20F4.17.
Binding of mAb MN20F4.17 is inhibited by a synthetic P1.10 peptide
The reactivity of mAb MN20F4.17 with a synthetic 14-amino-acid peptide was evaluated. The sequence of this peptide, HFVQNKQNQRPTLV, corresponded to the prototype P1.10 VR but lacked the terminal proline. The peptide did not react in ELISA when dried on to plates or in immunoblots when dot-blotted on to nitrocellulose filters, preventing a direct comparison of the binding of the peptide with whole cells of strain 21040 to mAb MN20F4.17. Recognition of the peptide by mAb MN20F4.17 was demonstrated by using increasing amounts of the 14-amino-acid peptide with pure P1.10 antibody in a whole-cell competitive ELISA. The peptide inhibited mAb binding to whole cells at greater than 1 mg peptide per well (Fig. 4) . The very high concentration of peptide required to out-compete the whole cells for binding to mAb suggested that the effect may be nonspecific. However, a different synthetic 15-amino-acid peptide (part of diphtheria toxin fragment D T B l with the amino acid sequence CGPIKNKMSESPNKT) did not inhibit binding of mAb MN20F4.17 to whole cells of strain 21040 at concentrations up to 10 mg per well (Fig. 4) . 
Identification of variation in the P1.10 family by chain termination fingerprinting

DISCUSSION
There are two levels of antigenic variation of PorA: (i) distinct subtype families in both VR1 and VR2 and (ii) variation within these VR families. The biology of this variation has implications for the use of PorA as a target for epidemiological characterization and as a vaccine component. The application of mAb reagents was a major advance in the identification of PorA variants by serosubtyping (Abdillahi & Poolman, 1987 , 1988a , and provided a degree of specificity and reproducibility that was difficult to achieve with polyclonal sera. A comprehensive childhood vaccine against meningococci has yet to be developed (Frasch, 1985 (Frasch, , 1989 Sanborn, 1987; Fine, 1991 ; Milagres e t al., 1994) and numerous protein antigens, including PorA, have been used as candidate vaccine components. Given the antigenic diversity of PorA, these vaccines must be multivalent if they are to protect against different meningococcal strains. The composition of such vaccines depends on accurate strain characterization to determine the diversity of the target antigen. A successful vaccine also requires information on the human response to these components. Although serological typing may have a role in the elucidation of these factors, there are several problems associated with the design of vaccines on the basis of data obtained with murine mAbs. First, serosubtyping can underestimate the antigenic diversity of PorA because members of a VR family react unpredictably with a given serosubtyping mAb. Consequently, accurate interpretation of serosubtyping data is dependent on the definition of the binding properties of the serosubtyping mAbs and on the standardization and control of assay conditions. Secondly, the 'prototype ' VR sequence, used to raise the antibody may not be representative of the subtypes found in the meningococcal population. For example, the P1.10a variant occurs more frequently than the prototype P1.10 in serogroup B and C strains. In addition, there is evidence that the epitopes identified by murine mAbs are not the same as the epitopes which are important in the human protective immune response (Delvig e t al., 1994) . Finally, it is likely that the epitopes within the circulating meningococcal population may change over time due to immune selection following carriage in humans.
